Experiments
Searchable full-text extractions: founding hypothesis, core claims, experimental setups, key results and statistics — pulled out of each paper as structure. Search a cell line, an assay or an entity (e.g. HUH7) and find every paper that worked with it. This corpus stands on its own: most entries carry no reproduction assessment (yet).
-
Full-text index only
Live-cell Pick-Seq (LiP-Seq): Interrogating ultra-rare mantle cell lymphoma persistent cells after CART19 therapy.
PMID 41855504 · PMC13234471 · Blood advances · 2026 · 8 claims · 7 setups
LiP-Seq is a novel platform combining multiplexed live-cell imaging and needle-based single-cell retrieval that enables transcriptomic profiling of ultrarare (down to 10^-6 frequency), viable persistent lymphoma cells
-
Full-text index only
Isoform-specific single-cell perturb-seq reveals distinct functions of alternative promoters in drug response.
PMID 41728950 · PMC12926921 · Nucleic acids research · 2026 · 5 claims · 8 setups
CRISPR-dCas9-based screens exhibit widespread promoter specificity, with untargeted promoters often showing compensatory upregulation to maintain overall gene expression
-
Full-text index only
Podoplanin-defined tumour plasticity and CCR7-mediated lymphatic metastasis in triple-negative breast cancer.
PMID 41957138 · PMC13226698 · British journal of cancer · 2026 · 8 claims · 8 setups
A PDPN-defined tumour cell mesenchymal shift, promoted by hypoxia, is required for efficient CCR7-driven lymphatic metastasis and tumour progression
-
Full-text index only
In vivo dual RNA-Seq uncovers key effectors of epithelial barrier disruption by an extracellular pathogen.
PMID 41634022 · PMC12966279 · Nature communications · 2026 · 8 claims · 8 setups
Dual RNA-Seq of L. interrogans-infected hamsters reveals the in vivo host-pathogen transcriptomic landscape during infection
-
Full-text index only
Vitamin C Conditioning Generates Tumor-Targeting CAR T Cells with Superior Cytotoxicity and Fitness in a Posttransplant Lymphoproliferative Disorder Tumor Model.
PMID 41416402 · PMC13136873 · Molecular cancer therapeutics · 2026 · 8 claims · 8 setups
VitC conditioning enhances transduction efficiency and proliferative capacity, yielding a higher yield of CD4+ and CD8+ CAR19-Ts